CEO of Progenics Pharmaceuticals, Inc. (PGNX) Mark Robert Baker buys 11,800 shares of PGNX on 11/19/2012 at an average price of $1.96 a share.

Progenics Pharmaceuticals, Inc. has a market cap of $63 million; its shares were traded at around $2.18 with and P/S ratio of 0.7.

This is the annual revenues and earnings per share of PGNX over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of PGNX.

CEO Recent Trades:

• CEO Mark Robert Baker bought 11,800 shares of PGNX stock on 11/19/2012 at the average price of 1.96. Mark Robert Baker owns at least 155,265 shares after this. The price of the stock has increased by 11.22% since.
• CEO Mark Robert Baker bought 49,793 shares of PGNX stock on 11/16/2012 at the average price of 1.82. Mark Robert Baker owns at least 143,465 shares after this. The price of the stock has increased by 19.78% since.
• CEO Mark Robert Baker bought 48,833 shares of PGNX stock on 11/15/2012 at the average price of 1.69. Mark Robert Baker owns at least 93,672 shares after this. The price of the stock has increased by 28.99% since.
• CEO Mark Robert Baker bought 1,162 shares of PGNX stock on 10/24/2012 at the average price of 2.96. Mark Robert Baker owns at least 44,839 shares after this. The price of the stock has decreased by 26.35% since.
• CEO Mark Robert Baker bought 1,036 shares of PGNX stock on 09/26/2012 at the average price of 3.32. Mark Robert Baker owns at least 43,677 shares after this. The price of the stock has decreased by 34.34% since.

This is the insider trade history vs. stock price of PGNX. For the complete insider trading history of PGNX, click here.

Directors and Officers Recent Trades:

• Senior VP Medical Affairs Robert J Israel sold 1,000 shares of PGNX stock on 07/02/2012 at the average price of 9.79. Robert J Israel owns at least 35,050 shares after this. The price of the stock has decreased by 77.73% since.
• Senior VP Medical Affairs Robert J Israel sold 1,000 shares of PGNX stock on 06/01/2012 at the average price of 8.51. Robert J Israel owns at least 38,383 shares after this. The price of the stock has decreased by 74.38% since.

For the complete insider trading history of PGNX, click here.

Why CEOs Are Buying Stocks Of Their Own Companies?

1. As legendary investor Peter Lynch said: "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."
2. TOP EXECUTIVES like CEOs and CFOs are savvy buyers of their companies' shares. One long-term study showed that they beat the market on average by six percentage points a year.
3. Another study found that the aggregated activities of insiders can serve as a good indicator to locate market bottoms. Insiders as a whole are smart investors of their own companies.

Click it to Check Out What the CEO Are Trading

More Gurufocus Links

Latest Guru Picks	Value Strategies
Warren Buffett Portfolio	Ben Graham Net-Net
Real Time Picks	Buffett-Munger Screener
Aggregated Portfolio	Undervalued Predictable
ETFs, Options	Low P/S Companies
Insider Trends	10-Year Financials
52-Week Lows	Interactive Charts
Model Portfolios	DCF Calculator
RSS Feed	Monthly Newsletters
The All-In-One Screener	Portfolio Tracking Tool